natgillin/translations-raw huggingface dataset:
Kommissionen vil arbejde for at sikre en smidig overgang. 
The Commission will work in view of ensuring a smooth transition.
Anbefaling 4 Đ Opstille bedre betingelser for rettidig gennemfżrelse af CEF-programmet a) Kommissionen accepterer anbefalingen. b) Kommissionen accepterer anbefalingen. c) Kommissionen accepterer anbefalingen. 
Recommendation 4 – Set better conditions for timely implementation of the CEF (a) The Commission accepts the recommendation. (b) The Commission accepts the recommendation. (c) The Commission accepts the recommendation.
Arbejdet med at sikre en bedre overvgning af projektets resultater set ud fra et politisk perspektiv er allerede pbegyndt. 
Works have already started to better monitor project results from a policy perspective.
Anbefaling 5 Đ Fastlžgge en performanceramme for at overvge projektresultaterne a) Kommissionen accepterer anbefalingen. 
Recommendation 5 – Redesign the performance framework to better monitor project results (a) The Commission accepts the recommendation.
Kommissionen understreger, at der i marts 2019 blev nedsat en arbejdsgruppe til dette forml, som omfatter medlemmer fra alle overordnede generaldirektorater og INEA, og som skal džkke alle tre CEF-sektorer. 
The Commission stresses that a working group for this purpose has been re-established in March 2019 which includes members from all parent DGs and INEA to cover all three CEF sectors.
Kommissionen agter at afslutte denne proces inden begyndelsen af den nžste programmeringsperiode (dvs. for CEF 2). b) Kommissionen accepterer anbefalingen. 
The Commission aims to conclude this process before the beginning of the next programming period (i.e. for CEF 2). (b) The Commission accepts the recommendation.
Revisionsholdet Revisionsrettens sžrberetninger pržsenterer resultaterne af dens revisioner vedrżrende EU-politikker og -programmer eller forvaltningsspżrgsml i forbindelse med specifikke budgetomrder. 
Audit team The ECA’s special reports set out the results of its audits of EU policies and programmes, or of management-related topics from specific budgetary areas.
Denne forvaltningsrevision blev udfżrt af Revisionsafdeling II - Investering i samhżrighed, vžkst og inklusion, der ledes af Iliana Ivanova, medlem af Revisionsretten. 
This performance audit was carried out by Audit Chamber II Investment for cohesion, growth and inclusion spending areas, headed by ECA Member Iliana Ivanova.
Revisionsarbejdet blev ledet af Oskar Herics, medlem af Revisionsretten, med stżtte fra kabinetschef Thomas Obermayr, attach Laura Gores, ledende administrator Pietro Puricella, opgaveansvarlig Jolita Korzuniene og revisorerne Susanna Rafalzik, Dieter Bckem, Thierry Lavigne, Nils Odins og Christian Verz. 
The audit was led by ECA Member Oskar Herics, supported by Thomas Obermayr, Head of Private Office and Laura Gores, Private Office Attaché; Pietro Puricella, Principal Manager; Jolita Korzuniene, Head of Task; Susanna Rafalzik, Dieter Böckem, Thierry Lavigne, Nils Odins and Christian Verzé, Auditors.
Thomas Everett og Cathryn Lindsay ydede sproglig stżtte. 
Thomas Everett and Cathryn Lindsay provided linguistic support.
Fra venstre til hżjre: Thomas Everett, Susanna Rafalzik, Dieter Bckem, Jolita Korzuniene, Oskar Herics, Cathryn Lindsay, Nils Odins, Laura Gores, Christian Verz, Pietro Puricella. 
From left to right: Thomas Everett, Susanna Rafalzik, Dieter Böckem, Jolita Korzuniene, Oskar Herics, Cathryn Lindsay, Nils Odins, Laura Gores, Christian Verzé, Pietro Puricella.
Tidslinje Begivenhed Dato Revisionsplanen vedtaget/Revisionen pbegyndt 4.7.2018/3.9.2018 Udkastet til beretning officielt sendt til Kommissionen (eller en anden revideret enhed) 28.6.2019 Den endelige beretning vedtaget efter den kontradiktoriske procedure 25.9.2019 Officielle svar fra Kommissionen (eller en anden revideret enhed) modtaget p alle sprog 31.10.2019 
Timeline Event Date Adoption of Audit Planning Memorandum (APM) / Start of audit 4.7.2018 / 3.9.2018 Official sending of draft report to Commission (or other auditee) 28.6.2019 Adoption of the final report after the adversarial procedure 25.9.2019 Commission’s (or other auditee’s) official replies received in all languages 31.10.2019
DA PDF ISBN 978-92-847-3670-6 doi:10.2865/114376 QJ-AB-19-014-DA-N DA HTML ISBN 978-92-847-3675-1 doi:10.2865/869210 QJ-AB-19-014-DA-Q 
EN PDF ISBN 978-92-847-3640-9 doi:10.2865/0477 QJ-AB-19-014-EN-N EN HTML ISBN 978-92-847-3665-2 doi:10.2865/845238 QJ-AB-19-014-EN-Q
Det er INEA's opgave at stżtte Kommissionen, projektivžrksžtterne og interessenterne ved at sżrge for ekspertise og programforvaltning vedrżrende infrastruktur-, forsknings-og innovationsprojekter inden for transport, energi og telekommunikation og at fremme synergier mellem disse aktiviteter. 
INEA’s mission is to support the Commission, project promoters and stakeholders by providing expertise and programme management to infrastructure, research and innovation projects in the fields of transport, energy and telecommunications and to promote synergies between these activities.
INEA forvalter 93 % af det samlede CEF-budget og 7 % af Horisont 2020-budgettet. 
INEA has been entrusted with 93 % of the total CEF budget and 7 % of the H2020 budget.
Vi konstaterede, at INEA har udfżrt sine delegerede opgaver som fastlagt i sit mandat og leveret de forventede fordele med visse begržnsninger, som skyldes rammeforhold. 
We found that INEA has fulfilled the delegated tasks as defined in its mandate and delivered expected benefits, with some limitations, related to framework constraints.
Vi fremsžtter anbefalinger til Kommissionen og INEA med sigte p forbedring af potentialet for synergier, styrkelse af rammen for INEA's forvaltning af de delegerede programmer, sikring af stżrre harmonisering og gennemsigtighed i procedurerne for udvžlgelse af CEF-projekter, skabelse af bedre betingelser for rettidig gennemfżrelse af CEF og žndring af performancerammen med henblik p bedre overvgning af CEF-projekternes resultater. 
We make recommendations to Commission and INEA aimed at improving the potential for synergies, strengthening the framework for INEA’s management of the delegated programmes, ensuring greater harmonisation and transparency of the CEF project selection procedures, setting better conditions for timely implementation of the CEF and redesigning the performance framework to better monitor CEF project results.
4, andet afsnit, TEUF. 50 
ECA special report pursuant to Article 287(4), second subparagraph, TFEU. 50
DA 2019 Sžrberetning 21 Bekžmpelse af antimikrobiel resistens: Der er sket fremskridt inden for dyresektoren, men denne sundhedstrussel udgżr fortsat en udfordring for EU nr. 
EN 2019 Special Report 21 Addressing antimicrobial resistance: progress in the animal sector, but this health threat remains a challenge for the EU NO
Kommissionens initiativer har endnu ikke fundet en lżsning p markedssvigtene inden for forskning i og udvikling af antimikrobielle stoffer Konklusioner og anbefalinger Bilag Bilag I - rligt salg af veterinžre antimikrobielle agenser til arter bestemt til fżdevareproduktion, i mg/PCU - udvalgte europžiske lande fra 2011 til 2016 Bilag II - ND4BB-projekterne angivet i forhold til processen for udvikling af lžgemidler Akronymer og forkortelser Glossar Kommissionens svar Revisionsholdet Tidslinje 58-61 62-75 3 
Commission initiatives have not yet resolved the market failures in antimicrobial research and development Conclusions and recommendations Annexes Annex I Đ Annual sales of veterinary antimicrobial agents for food-producing species, in mg/PCU, for selected European countries, from 2011 to 2016 Annex II Đ ND4BB projects mapped against the drug development process Acronyms and abbreviations Glossary Replies of the Commission Audit team Timeline 58-61 62-75 3
Resum I Antimikrobiel resistens (AMR) - dvs. nr mikrober udvikler resistens over for lžgemidler, som tidligere kunne bekžmpe dem - udgżr en stigende trussel mod den globale sundhed. 
Executive summary I Antimicrobial resistance (AMR) - when microbes develop resistance against medicines that were previously able to fight them - is a growing threat to global health.
Det Europžiske Center for Forebyggelse af og Kontrol med Sygdomme rapporterede, at den allerede medfżrer 33 000 dżdsfald i EU/EŻS hvert r, hovedsagelig p grund af infektioner erhvervet p hospitaler og i andre sundhedsmiljżer. 
The European Centre for Disease Prevention and Control reported that it already leads to 33 000 deaths each year in the EU/EEA, mostly due to infections in hospitals and other healthcare settings.
Verdenssundhedsorganisationens "One Health"-princip, som tager hensyn til menneskers sundhed, dyrs sundhed og miljżet, anerkender, at en integreret tilgang til antimikrobielle stoffer er nżdvendig. 
The World Health OrganisationŐs ŇOne HealthÓ principle, which considers human health, animal health and the environment, recognises that an integrated approach to antimicrobials is needed.
II Bekžmpelsen af antimikrobiel resistens er kompliceret. 
II Fighting against antimicrobial resistance is complicated.
Det er en udfordring at anvende gode foranstaltninger til forebyggelse og kontrol af infektioner i praksis (bl.a. s basale praksis som hndvask). 
It is challenging to apply good infection prevention and control measures in practice (including practices as basic as hand washing).
Det er ogs en udfordring at anvende de eksisterende antimikrobielle stoffer forsigtigt (bde til behandling af mennesker og dyr), dvs. at bruge det rigtige lžgemiddel korrekt og kun, nr det er nżdvendigt. 
It is also challenging to use existing antimicrobials prudently (both to treat humans and animals), meaning using the right drug correctly and only when needed.
Endelig er der ikke opdaget nogen nye klasser af antibiotika i mange r. 
Finally, no new classes of antibiotics have been discovered for many years.
III I EU hżrer beskyttelse af menneskers sundhed under medlemsstaternes kompetence. 
III In the EU, human health is a Member State competence.
Artikel 6 og 168 i traktaten om Den Europžiske Unions funktionsmde giver Unionen kompetence til at understżtte, koordinere, supplere og tilskynde til samarbejde mellem medlemsstaterne med henblik p beskyttelse og forbedring af folkesundheden. 
Article 6 and 168 of the Treaty on the Functioning of the European Union give the Union a mandate to support, coordinate, supplement and encourage cooperation between Member States for the protection and improvement of human health.
EU-retten anerkender antimikrobiel resistens som en alvorlig gržnseoverskridende sundhedstrussel, som kržver en indsats fra EU. 
Antimicrobial resistance is recognised by EU law as a serious cross-border threat to health, where EU action is required.
Endvidere har Kommissionen klar kompetence til at gribe ind p omrderne dyresundhed, fżdevaresikkerhed og forskning: De er alle relevante i forbindelse med antimikrobiel resistens. 
Furthermore, there is clear Commission competence to act in veterinary issues, food safety, and research: all of which are relevant for antimicrobial resistance.
IV Vores revision undersżgte den stigende trussel fra antimikrobiel resistens samt EU's seneste politiske initiativer. 
IV Our audit considered the rising threat of antimicrobial resistance and recent EU policy initiatives.
Vi undersżgte, hvordan Kommissionen og Det Europžiske Center for Forebyggelse af og Kontrol med Sygdomme (ECDC) forvaltede ressourcer, som skal stżtte medlemsstaternes One Health-tilgang til antimikrobiel resistens, og om den ramme, der skal styrke den forsigtige anvendelse af veterinžre antimikrobielle stoffer og overvgningen af antimikrobiel resistens i fżdevarer, blev anvendt korrekt. 
We examined how the Commission and the European Centre for Disease Prevention and Control (ECDC) managed resources aimed at supporting Member States One Health approach to antimicrobial resistance, and whether the framework to improve the prudent use of veterinary antimicrobials and monitor antimicrobial resistance in food was being well applied.
Vi undersżgte ogs, hvordan Kommissionen stżttede AMR-relateret forskning. 
We also examined how the Commission supported AMR related research.
V Vi konkluderer, at Kommissionens og agenturernes aktiviteter har medfżrt visse fremskridt, f.eks. for s vidt angr veterinžre og fżdevarerelaterede spżrgsml. 
V We conclude that the activities of the Commission and agencies have led to some progress, for example, in veterinary and food related issues.
Hidtil er der er imidlertid ikke meget, der tyder p, at sundhedsbyrden i forbindelse med AMR er blevet reduceret i EU. 
However, there is little evidence to date that the health burden of AMR has been reduced in the European Union. 4
VI Kommissionens og ECDC's stżtte med henblik p at styrke medlemsstaternes One Health-tilgang til AMR var vžrdifuld, men havde kun medfżrt f pviselige fremskridt med hensyn til at reducere AMR. 
VI The Commission and ECDC support to strengthen Member States One Health approach to AMR was valuable, but had resulted in little demonstrable progress in reducing AMR.
Den fžlles aktion om antimikrobiel resistens med henblik p at stżtte de nationale One Health-politikker fremmede samarbejdet mellem medlemsstaterne, men der var udfordringer for s vidt angr den bžredygtige gennemfżrelse af aktionens resultater. 
The Joint Action on antimicrobial resistance, to support national One Health policies, facilitated cooperation between Member States but faced challenges to the sustainable implementation of its results.
En nylig undersżgelse finansieret af Kommissionen og udfżrt under ledelse af OECD anviste omkostningseffektive muligheder, som medlemsstaterne kunne bruge for at reducere antimikrobiel resistens p hospitaler og i andre sundhedsmiljżer. 
A recent Commission funded study led by the OECD was a compass for cost effective options for Member States to reduce antimicrobial resistance in hospitals and other healthcare settings.
Hverken de medlemsstater, vi besżgte, eller Kommissionen brugte konsekvent resultatindikatorer til at overvge fremskridt, dataene om infektioner erhvervet i sundhedsvžsenet - som er den vigtigste kilde til AMR-infektioner - var ufuldstžndige, og kendskabet til AMR i miljżet var utilstržkkeligt p tidspunktet for vores revision. 
Outcome indicators were not consistently used by the Member States we visited, or by the Commission, to monitor progress; data on health care associated infections, which are the primary source of AMR infections, was incomplete; and, at the time of our audit, there was insufficient knowledge about AMR in the environment.
VII Den forsigtige anvendelse af veterinžre antimikrobielle stoffer styrkes generelt i medlemsstaterne. 
VII The prudent use of veterinary antimicrobials is generally improving in the Member States.
Mellem 2011 og 2016 faldt salget af veterinžre antimikrobielle stoffer med 20 %. 
Between 2011 and 2016, sales of veterinary antimicrobials reduced by 20 %.
Der er dog betydelige forskelle mellem medlemsstaterne, og forbruget af visse antimikrobielle stoffer er fortsat for hżjt. 
However, there are big differences between the Member States, and consumption of some antimicrobials is still too high.
Den seneste EU-lovgivning om lžgemidler og foder adresserede nogle kendte svagheder. 
Recent EU legislation on medicinal products and feed addressed some known weaknesses.
Den fremtidige fžlles landbrugspolitik giver mulighed for yderligere at styrke EU's rammer for hndtering af AMR. 
The future Common Agricultural Policy provides an opportunity to further strengthen the EU framework for dealing with AMR.
VIII Markedet for antimikrobielle stoffer mangler kommercielle incitamenter til at udvikle nye behandlinger. 
VIII The antimicrobials market lacks commercial incentives to develop new treatments.
Midler fra EU-budgettet er en vigtig investeringskilde for forskningsomrdet og har skabt strukturer til at fremskynde udviklingen af nye antimikrobielle stoffer. 
Funding from the EU budget is a major source of investment for research, and has created structures to speed up the development of new antimicrobials.
EU-finansierede offentlig-private forskningsinitiativer har imidlertid oplevet forsinkelser, og der har ikke vžret nogen gennembrud endnu. 
But EU funded public Đ private research initiatives experienced delays, and there have been no breakthroughs yet.
Kommissionen har ikke foretaget en grundig evaluering af sin tilgang til forskning i antimikrobielle stoffer, og dens handlingsplan adresserer ikke visse af de specifikke udfordringer, som AMR-forskningen str over for. 
The Commission has not comprehensively evaluated its approach to antimicrobial research, and its action plan does not address some of the specific challenges facing AMR research.
Der er stort set ingen konkrete initiativer til at afhjžlpe markedssvigt, som pvirker leveringen af nye antimikrobielle stoffer. 
Concrete initiatives to address market failures affecting provision of new antimicrobials are largely absent.
IX P grundlag af vores konklusioner fremsžtter vi anbefalinger, som sigter mod at styrke Kommissionens reaktion p antimikrobiel resistens via bedre stżtte til medlemsstaterne, fremme af forsigtig brug af antimikrobielle stoffer og bedre overvgning af antimikrobiel resistens samt styrkelse af forskningsstrategierne. 
IX Based on our conclusions, we make recommendations aimed at strengthening the CommissionŐs response to antimicrobial resistance through better support to Member States; promoting the prudent use of antimicrobials and better monitoring of antimicrobial resistance; and strengthening strategies for research. 5
Indledning Hvad er antimikrobiel resistens? 01 Antimikrobielle stoffer anvendes til behandling af mennesker, dyr og planter. 
Introduction What is Antimicrobial Resistance 01 Antimicrobials are used to treat people, animals and plants.
Antimikrobiel resistens (AMR) opstr, nr mikrober (bakterier, vira, parasitter og svampe) udvikler resistens over for lžgemidler, som tidligere var i stand til at bekžmpe dem, og dermed gżr behandlingen mindre effektiv eller fuldstžndig ineffektiv. 
Antimicrobial resistance (AMR) happens when microbes (bacteria, viruses, parasites, and fungi) develop resistance against medicines that were previously able to fight them, making the treatment less efficient or completely ineffective.
AMR udvikler sig naturligt med tiden, normalt gennem genetiske žndringer1, men processen bliver hurtigere, nr antimikrobielle stoffer overforbruges eller misbruges, dvs. ikke anvendes forsigtigt - en forsigtig anvendelse indebžrer, at det rigtige lžgemiddel anvendes, nr det er nżdvendigt, med den rigtige dosis, hyppighed og varighed (figur 1 viser, hvordan AMR udvikler sig). 
AMR develops naturally over time, usually through genetic changes1, but it accelerates when antimicrobials are overused or misused i.e. are not used prudently Đ meaning the right drug is used when needed, at the right dose, frequency, and duration (Figure 1 shows how AMR develops).
Figur 1 - Hvordan antimikrobiel resistens udvikler sig Et hżjt antal bakterier, herunder gode bakterier (beskytter kroppen mod sygdom), sygdomsforrsagende bakterier og nogle f resistente bakterier. 
Figure 1 Đ How antimicrobial resistance develops High number of bacteria including good bacteria (protecting body from illness), bacteria causing illness and few resistant bacteria.
Antibiotika držber alle bakterierne (bde de gode og de sygdomsforrsagende), undtagen de antibiotikaresistente bakterier. 
Antibiotics kills off all bacteria (the good ones and ones causing the illness) except the antibiotic resistant bacteria.
De lžgemiddelresistente bakterier har nu mulighed for at vokse og tage over. 
Drug resistant bacteria has now conditions to grow and take over.
De lžgemiddelresistente bakterier kan overfżre deres mutation til andre bakterier. 
Drug resistant bacteria can transfer its mutation to other bacteria.
Kilde: Revisionsretten p grundlag af oplysninger fra De Forenede Staters centre for kontrol med og forebyggelse af sygdomme (CDC). 
Source: ECA based on United States Centers for Disease Control and Prevention (CDC).
02 Verdenssundhedsorganisationen (WHO) har identificeret AMR som en alvorlig trussel mod den globale sundhed, udvikling og fżdevaresikkerhed2. 
02 The World Health Organisation (WHO) identified AMR as a serious threat to global health, development and food security2.
Det Europžiske Center for Forebyggelse af og Kontrol med Sygdomme (ECDC) har rapporteret3, baseret p data fra 2015, at 33 000 mennesker dżr hvert r i EU/Det Europžiske Antimicrobial resistance - Key facts, WHO, februar 2018. 
The European Centre for Disease Prevention and Control (ECDC) reported3 that 33 000 people die each year, based on Antimicrobial resistance Đ Key facts, WHO, February 2018.
WHO (2017), Antibiotic Resistance Fact Sheet, Verdenssundhedsorganisationen. 
WHO (2017), Antibiotic Resistance Fact Sheet, World Health Organization.
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015, The Lancet, 2018. 
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015, the Lancet, 2018.
Żkonomiske Samarbejdsomrde (EŻS) som fżlge af infektioner forrsaget af lžgemiddelresistente bakterier. 
2015 data, in the EU / European Economic Area (EEA) from infections caused by drug resistant bacteria.
AMR genererer yderligere rlige omkostninger p 1,5 milliarder4 p grund af ekstra sundhedsudgifter og produktivitetstab. 
AMR generates additional yearly costs of Ű1.5 billion4 due to extra healthcare costs and productivity losses.
Infektioner forrsaget af organismer, der har udviklet resistens, erhverves normalt p hospitaler og i andre sundhedsmiljżer og kan kržve lžngere og dyrere behandlinger, hvoraf nogle har alvorlige bivirkninger (f.eks. nyresvigt), og de indebžrer en hżjere risiko for, at patienterne dżr. 
Infections caused by organisms that have developed resistance, usually acquired in hospitals and other healthcare settings, may require lengthier and costlier treatments, some with serious side effects (e.g. renal failure), and carry a higher risk of death for patients.
03 Nžsten 40 % af sundhedsbyrden i forbindelse med AMR skyldes bakterier, som er resistente over for sidstevalgsantibiotika (ssom carbapenemer og colistin). 
03 Nearly 40 % of the health burden of AMR is caused by bacteria resistant to last-line antibiotics (such as carbapenems and colistin).
Nr sidstevalgsantibiotika ikke lžngere virker, er det vanskeligt og mske umuligt at behandle inficerede patienter5. 
When last-line antibiotics are no longer effective, it is difficult and may be impossible to treat infected patients5.
04 Anvendelsen af antimikrobielle stoffer til dyr bestemt til fżdevareproduktion udgżr ca. to tredjedele af den samlede anvendelse i EU/EŻS6. 
04 In the EU / EEA, about two thirds of total antimicrobial use is for food producing animals6.
Nogle af disse ender i miljżet7. 
Some of these then end up in the environment7.
Det er dokumenteret, at reduktioner i anvendelsen af antimikrobielle stoffer til dyr bestemt til fżdevareproduktion medfżrer reduktioner i forekomsten af antimikrobielt resistente mikroorganismer i disse dyr8. 
There is evidence that reductions in the use of antimicrobials in food-producing animals lead to reductions in the presence of antimicrobial-resistant microorganisms in these animals8.
05 Antimikrobielle stoffer, som anvendes til behandling af sygdomme, der kan overfżres mellem dyr og mennesker, f.eks. campylobacteriose og salmonellose, bliver efterhnden mindre effektive. 
05 Antimicrobials used to treat diseases that can be transmitted between animals and humans, such as campylobacteriosis and salmonellosis, are becoming less effective.
Resistens over for visse antimikrobielle stoffer varierer alt efter lande og mikroorganismer. 
Resistance to certain antimicrobials varies between different countries and type of microorganisms.
EU Action on Antimicrobial Resistance, Europa-Kommissionen, 2017. 
EU Action on Antimicrobial Resistance, European Commission, 2017.